Harrow Corporation, a prominent eyecare pharmaceutical company based in North America, has announced that it will be releasing its financial results for the third quarter of 2024 on November 13, 2024, after the market closes. The company will also be sharing its third quarter Letter to Stockholders on its website, harrow.com.
To discuss the financial results and provide a business update, Harrow will be hosting a conference call and live webcast on November 14, 2024, at 8:00 a.m. Eastern Time. Participants can join the conference call through the webcast on the “Investors” page of Harrow’s website. For those joining via telephone, registration in advance is required. Upon registration, detailed instructions will be provided, including a unique dial-in number and PIN for accessing the call. A replay of the conference call and webcast will be available on the company’s website for one year.
Harrow, Inc. is known for its commitment to discovering, developing, and commercializing innovative ophthalmic pharmaceutical products for the North American market. The company aims to make its prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients, helping eyecare professionals in preserving the gift of sight.
For more information about Harrow, interested individuals can visit harrow.com. For any inquiries, please contact Jamie Webb, Director of Communications and Investor Relations, at jwebb@harrowinc.com or 615-733-4737.
The upcoming release of the financial results for the third quarter of 2024 is highly anticipated by investors, analysts, and stakeholders in the eyecare pharmaceutical industry. It will provide valuable insights into Harrow’s performance, growth, and future prospects. The conference call and webcast on November 14, 2024, present an opportunity for participants to gain a deeper understanding of the results and hear directly from the company’s management team.
In addition to discussing the financial results, the business update during the conference call will likely cover key initiatives, product developments, market trends, and strategic priorities. This information can offer valuable context for investors and stakeholders evaluating Harrow’s performance and prospects in the eyecare pharmaceutical market.
Overall, the announcement of the financial results release date and the upcoming conference call demonstrate Harrow’s commitment to transparency, communication, and stakeholder engagement. By sharing timely and relevant information, the company aims to keep investors and stakeholders informed and involved in its progress and developments.
